A registered nurse at the Altoona Center for Clinical Research in Duncansville, PA begins the process of preparing refrigerated doses of Pfizer's Lyme disease vaccine (Gary M. Baranec/AP Images)

Pfiz­er cuts CRO uni­corn from Ly­me vac­cine tri­al in dis­pute over con­duct

Pfiz­er is end­ing its work with re­search con­trac­tor Care Ac­cess on an 18,000-pa­tient Ly­me dis­ease vac­cine tri­al, ac­cord­ing to an in­ter­nal email re­viewed by End­points News, widen­ing the breach that has emerged be­tween the drug gi­ant and the rich­ly-val­ued re­search start­up in re­cent days.

Last week, Pfiz­er said it was re­mov­ing thou­sands of pa­tients re­cruit­ed by Care Ac­cess from the Phase III work, cit­ing is­sues with how Care Ac­cess had con­duct­ed its part of the tri­al. At the time, it was un­clear whether any col­lab­o­ra­tion be­tween the com­pa­nies on the Ly­me re­search would con­tin­ue and if Care Ac­cess would re­cruit new pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.